Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours
1992 (English)In: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 28A, no 10, 1647-1650 p.Article in journal (Refereed) Published
24 patients with malignant carcinoid tumours received octreotide and interferon alfa (IFN-alpha). All the patients initially received octreotide 50-100 micrograms, twice daily. When progressive symptoms or increasing biochemical markers were observed, the daily dose was raised to a median 300 micrograms. If the initial dose proved ineffective or if no improvement was seen after escalation, IFN-alpha was added (median 9 MU subcutaneously per week). After the addition of IFN-alpha, 17 of the 22 patients (77%) with elevated urinary 5-hydroxyindoleacetic acid showed a significant (> 50%) reduction. Only 1 patient progressed and 4 had continuously stable biochemical disease. No significant reduction in tumour size was noted; in 5 patients, the tumour continued to grow despite decreasing hormone levels. 18 patients had carcinoid syndrome when IFN-alpha was added in 10 (56%) symptoms ameliorated. Thus, the addition of IFN-alpha is beneficial for patients with malignant carcinoid tumours that progress and/or who do not respond to octreotide.
Place, publisher, year, edition, pages
1992. Vol. 28A, no 10, 1647-1650 p.
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Female, Humans, Hydroxyindoleacetic Acid/urine, Interferon-alpha/therapeutic use, Male, Malignant Carcinoid Syndrome/mortality/*therapy/urine, Middle Aged, Octreotide/therapeutic use
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-21438PubMedID: 1382492OAI: oai:DiVA.org:uu-21438DiVA: diva2:49211